Edgewise Therapeutics, Inc. (EWTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Boulder, CO, United States. The current CEO is Kevin Koch.
EWTX has IPO date of 2021-03-26, 117 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $3.56B.
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for musculoskeletal diseases, particularly rare genetic muscle disorders. The company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy, and has completed Phase 1 clinical trials. Edgewise is building a pipeline of precision medicine candidates that target key muscle proteins and modulators to treat genetically defined muscle disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company is advancing innovative therapeutic approaches for patients with serious muscle-wasting conditions.
